China’s Fermentation Giants Turn to Mycoprotein as Pharma Margins Shrink

China’s largest fermentation manufacturers are shifting their focus toward mycoprotein, yeast proteins, and precision-fermented fats due to shrinking margins in the pharmaceutical sector. A report by the Good Food Institute (GFI) APAC highlights how the extensive production capacity, technical expertise, and low operating costs built up in the pharmaceutical industry are now being redirected towards alternative protein production.

This pivot is supported by government policies promoting alternative proteins as part of China’s biomanufacturing strategy. Companies like Fushine Biotech and More Meat are expanding mycoprotein production capacity, indicating a growing interest in novel foods. International startups are encouraged to engage with Chinese partners for lower costs and faster scale-up, while also considering factors like intellectual property protection and geopolitical risks in entering the market. Ultimately, the shift in focus towards alternative proteins in China’s fermentation ecosystem presents opportunities for both local and international players in the industry.